PIPE-791

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NamePIPE-791
Drug Alias NamePIPE-791
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonistsPositron-emission tomography enhancers
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsChronic PainLow Back PainMultiple Sclerosis, Chronic Progressive +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesContineum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesContineum Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsChronic PainLow Back PainMultiple Sclerosis, Chronic Progressive +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A